News and Trends 7 Oct 2021
Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery
Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts to use artificial intelligence to…
Mark Zipkin
About
Mark Zipkin is a freelance writer and consultant for the biotech and pharma industry, and a Central Operations Analyst for safety app Citizen. He was previously a staff writer at BioCentury, and has worked for SpringerNature journals including Nature Biotechnology and Nature Neuroscience. Mark lives in New Jersey with his wife and three children. Follow Mark on Twitter @MarkZipkin.Articles by Mark Zipkin
Expert Advice 5 Oct 2021
How to Choose the Right Headquarters for Your Biotech Startup
Choosing where to plant your biotech company’s roots is a fundamental question driven by access to capital, talent, and infrastructure.…
Expert Advice 18 Aug 2021
How to Pitch Your Biotech Startup to a Life Sciences Investor
You’ve got the idea. You’ve got the science. You’ve got the team. Now all you need is the money, but…
News and Trends 17 Aug 2021
Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
Sanofi’s acquisition of its partner Translate Bio is a clear sign that pharmaceutical companies are interested in messenger RNA technologies…
ADVERTISEMENT
News and Trends 28 Jul 2021
Microbiome Medicines Could Power Up CAR-T Cell Therapies
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings that gut bacteria metabolites may…
Expert Advice 19 Jul 2021
How to Protect Your Intellectual Property as a Biotech Startup
Biotechs always start with great scientific ideas, but if you can’t protect them, you can’t see them through to execution.…
Expert Advice 16 Jun 2021
What Makes a Biotech Executive Stand Out?
Talented executives are always in demand in the biotech industry. Leaders who stand out in the field demonstrate flexibility to…
News and Trends 28 May 2021
Startup Creator Launched to Fill Europe’s Microbiome Translational Gap
With a €49M ($60M) Series A, the French firm eureKARE debuted this month with the goal of priming the translational…
Expert Advice 17 May 2021
How to Spend Your Biotech Startup’s Money
Biotech investment rounds tend to draw big headlines, but experienced players know the real work is done in between them.…
News and Trends 29 Apr 2021
BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly…
ADVERTISEMENT
News and Trends 15 Apr 2021
Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens
The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed…
News and Trends 1 Apr 2021
Have European Investors Missed the Exosome ‘Gold Rush’?
When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled that investors are taking exosome…